Jeffrey Flier, former Dean at Harvard Medical School, writes in STAT on How Pfizer ended up passing on my GLP-1 work back in the early 90s. Flier kicks off with Despite extremely promising results, Pfizer, the major funder of the work in alliance with California Biotechnology, abandoned the effort around 1991 after mistakenly concluding that the GLP-1 therapeutic approach was not worth continuing. He states that he is not trying to take credit for the GLP-1 market, rather that the story offers valuable lessons on drug development for pharmaceutical companies, researchers, and the general public alike. The article describes the early stages of drug development and testing from 1987, with Pfizer against an injectable GLP-1 version, and a focus on a way to deliver GLP-1 via transnasal, transcutaneous, or oral administration
Clean & Thoughtful Ingredients Made with carefully sourced ingredients and manufactured following quality standards for dietary supplements
This dual approach maximizes both overall and localized growth
These bland foods are easy to digest and can help firm up stools
In the world of conventional medicine, this stage is controversial in terms of treatment